Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(R) (tafasitamab) for Follicular Lymphoma in Brazil
(TSX:GUD),(NASDAQ:INCY), MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI(R) (tafasitamab) in combination with rituximab and […]